DOI: 10.36347/sjmcr.2022.v10i09.005

Pages: 872-878

The outbreak of novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan, China caused a worldwide pandemic. Both symptomatic and asymptomatic carriers were responsible for the transmission of the diseases. Many studies showed high infectivity of the virus. It is therefore urgent to control the transmission of the virus and treat patients infected with SARS-CoV-2 virus. Many evidences have suggested that involvement of human hyperactivation and severe acute respiratory syndrome plays an important role in pathogenesis of critically ill patients with COVID-19. Therefore, repurposing of approved drugs has been used to tackle COVID-19 as the pharmacokinetic and safety profile of these drugs are known. Several immunomodulatory drugs such as disease modifying anti-rheumatic drugs (DMARD) have been proposed as potential therapies for treatment of COVID-19. In this Review we discuss human immune response to virus, pathogenesis of COVID-19 and potential drugs for COVID-19.